Stanford University
Stanford, California, 94305, United States
NCT Number: NCT03810378
The objective of this study is to compare two metabolically distinct diets, WFKD vs Med-Plus, in order to examine the potential benefits, and unintended consequences, of going beyond a focus on maximally avoiding added sugars and refined grains, to also avoiding legumes, fruits, and whole grains.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Stanford, California, 94305, United States
The proposed randomized clinical trial will investigate differential population-specific effects of two low-carbohydrate (low-carb) diet patterns, addressing a gap in the evidence base in this area that will lead to 1) improved treatment strategies for common adverse clinical conditions, 2) improved health for these individuals, and 3) long-term decreases in health care costs. This impactful research will advance the field of personalized and precision medicine.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Identify exclusion criteria.
Exclusion criteria
Participants will follow the Med-Plus diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
Participants will follow the WFKD diet for 12 weeks, then switch to the alternate diet for another 12 weeks (no washout period).
Time frame: Baseline and 12 weeks
Change from baseline in HbA1c at 12 weeks of each phase
Time frame: Baseline and 12 weeks
Change from baseline in alpha diversity at 12 weeks of each phase. We will be using number of observed sequence variants ("species") determined by standard 16S rRNA amplicon sequencing (V3-V5 region followed by DADA2 to define error-corrected sequence variants) as our primary metric of alpha diversity. Higher alpha diversity is better. The units are the # of sequence variants.
Time frame: Baseline and 12 weeks
Change from baseline in composite of short-chain fatty acids (SCFA) concentration (ug/g stool: acetate + propionate + butyrate) at 12 weeks of each phase.
Time frame: Baseline and12 weeks
Change from baseline in LDL cholesterol at 12 weeks of each phase.
Time frame: Baseline and 12 weeks
Change from baseline in HDL cholesterol at 12 weeks of each phase.
Time frame: Baseline and 12 weeks
Change from baseline in triglycerides at 12 weeks of each phase.
Time frame: Baseline and 12 weeks
Change from baseline in fasting insulin at 12 weeks of each phase.
Time frame: Baseline and 12 weeks
Change from baseline in blood pressure at 12 weeks of each phase.
Time frame: Baseline and 12 weeks
Average satisfaction level with meals at 12 weeks of each phase (WFKD compared to Med-Plus phase) using a 5-point Likert scale (1=not at all satisfied; 2=slightly satisfied; 3=moderately satisfied; 4=very satisfied; 5=extremely satisfied).
Time frame: Baseline and 12 weeks
Adherence to diet protocols 12 weeks of each phase in subjects with Diabetes compared to subjects with prediabetes, according to 3-day food records.
Stanford University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05144737
Body Weight, Cardiovascular Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT05280496
Diabetes Mellitus, Diabetes Mellitus, Type 2
Boston, Massachusetts, United States
View Trial DetailsNCT03283657
Body Weight, Body Weight Changes
Chicago, Illinois, United States
View Trial DetailsNCT05260983
Diabetes, Diabetes Mellitus
Eugene, Oregon, United States
View Trial Details